CARDIFF ONCOLOGY CRDF 深 沪
等待开盘 09-16 09:30:00 美东时间
2.045
-0.005
-0.24%
华盛通- 最 高2.08
- 今 开2.08
- 成交量 64.19万股
- 最 低 1.97
- 昨 收 2.05
- 总市值 1.36亿
- 52周最高 5.6395
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.90
- 委 比 -59.11%
- 总股本 6652.59万
- 历史最高 977.76
- 量 比 0.92
- 振 幅 5.37%
- 历史最低 0.701
- 每 手 1
- 风险率 0.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cardiff Oncology to Participate in Three Upcoming Investor Conferences
Cardiff Oncology宣布其管理层将参加2025年9月的三场投资者会议，包括Wells Fargo、Morgan Stanley和H.C. Wainwright的年度医疗与投资大会。公司通过PLK1抑制剂开发抗癌疗法，重点治疗结直肠癌、胰腺癌等。会议详情见公司网站。
08-28 20:05
HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Lowers Price Target to $10
HC Wainwright & Co. analyst Robert Burns maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy and lowers the price target from $18 to $10.
08-06 20:06
Cardiff Oncology Q2 EPS $(0.21) Misses $(0.20) Estimate, Sales $121.00K Beat $92.86K Estimate
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5 percent. This is a 19.23 percent increase over losses of $(0.26) per share from
07-30 04:14
Cardiff Oncology Announces Data From Ongoing Randomized Phase 2 First-Line RAS-Mutated mCRC Clinical Trial
– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) –– Early PFS data show a trend favoring 30mg onvansertib dose arm
07-30 04:12
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update
Cardiff Oncology appointed Dr. Roger Sidhu as Chief Medical Officer, completed enrollment in the CRDF-004 Phase 2 trial for first-line RAS-mutated metastatic colorectal cancer (mCRC), and announced positive data from an investigator-initiated trial of onvansertib in combination with paclitaxel in metastatic triple negative breast cancer (mTNBC) at ASCO 2025. The company had $71.0 million in cash and investments as of June 30, 2025, with a project...
07-29 20:05
Ladenburg Thalmann Initiates Coverage On Cardiff Oncology with Buy Rating, Announces Price Target of $19
Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on Cardiff Oncology (NASDAQ:CRDF) with a Buy rating and announces Price Target of $19.
07-09 02:44
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
Jefferies Initiates Coverage On Cardiff Oncology with Hold Rating, Announces Price Target of $3.5
Jefferies analyst Maury Raycroft initiates coverage on Cardiff Oncology (NASDAQ:CRDF) with a Hold rating and announces Price Target of $3.5.
06-24 20:24
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC
Cardiff Oncology has appointed Roger Sidhu, MD, as Chief Medical Officer, with over 20 years of oncology experience. The company will share additional clinical data from its Phase 2 CRDF-004 trial on July 29, evaluating onvansertib for first-line RAS-mutated metastatic colorectal cancer.
06-17 20:05
Cardiff Oncology Presents Data From Investigator-Initiated Phase 1b Clinical Trial Evaluating Onvansertib In Combination With Paclitaxel In Patients With mTNBC At 2025 ASCO Annual Meeting
– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate –– The trial evaluated three doses of onvansertib in
06-03 04:11
